Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab.

Autor: Fukui, Tomoya¹ (AUTHOR) tofukui@med.kitasato-u.ac.jp, Hosotani, Shinji¹ (AUTHOR), Soda, Itaru² (AUTHOR), Ozawa, Takahiro¹ (AUTHOR), Kusuhara, Seiichiro¹ (AUTHOR), Kakegawa, Mikiko I.¹ (AUTHOR), Kasajima, Masashi¹ (AUTHOR), Hiyoshi, Yasuhiro¹ (AUTHOR), Igawa, Satoshi¹ (AUTHOR), Yokoba, Masanori³ (AUTHOR), Mitsufuji, Hisashi⁴ (AUTHOR), Kubota, Masaru³ (AUTHOR), Katagiri, Masato³ (AUTHOR), Sasaki, Jiichiro⁵ (AUTHOR), Ishiyama, Hiromichi² (AUTHOR), Naoki, Katsuhiko¹ (AUTHOR)

Publikováno v: Thoracic Cancer. Apr2020, Vol. 11 Issue 4, p1005-1014. 10p.

Amrubicin monotherapy for elderly patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective study

Autor: Sone, Hideyuki, Igawa, Satoshi, Kasajima, Masashi, Ishihara, Mikiko, Hiyoshi, Yasuhiro, Hosotani, Shinji, Ohe, Shuntaro, Ito, Hiroki, Kaizuka, Nobuki, Manaka, Hiroya, Fukui, Tomoya, Mitsufuji, Hisashi, Kubota, Masaru, Katagiri, Masato, Sasaki, Jiichiro, Naoki, Katsuhiko

Publikováno v: Thoracic Cancer

Background Previous studies have shown amrubicin (AMR) to be an effective second‐line treatment option for small‐cell lung cancer (SCLC). However, the efficacy of AMR in elderly patients with relapsed SCLC has not been sufficiently evaluated. Met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a0c72a43a7b2eb34a8f2f8b7e5de4c5b
http://europepmc.org/articles/PMC6166081

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.